Singapore markets closed

SpringWorks Therapeutics, Inc. (SWTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
42.34+0.50 (+1.20%)
As of 11:52AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 3.10B
Enterprise value 2.67B
Trailing P/E 21.09
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)104.32
Price/book (mrq)5.46
Enterprise value/revenue 100.87
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.78
52-week change 342.07%
S&P500 52-week change 323.63%
52-week high 353.92
52-week low 318.00
50-day moving average 340.43
200-day moving average 337.88

Share statistics

Avg vol (3-month) 3811k
Avg vol (10-day) 3598.77k
Shares outstanding 574.09M
Implied shares outstanding 674.09M
Float 872.52M
% held by insiders 12.20%
% held by institutions 1110.65%
Shares short (28 Jun 2024) 410.42M
Short ratio (28 Jun 2024) 413.02
Short % of float (28 Jun 2024) 417.03%
Short % of shares outstanding (28 Jun 2024) 414.06%
Shares short (prior month 31 May 2024) 410.8M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)-447.16%

Management effectiveness

Return on assets (ttm)-36.63%
Return on equity (ttm)-63.12%

Income statement

Revenue (ttm)26.45M
Revenue per share (ttm)0.40
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -357.1M
Net income avi to common (ttm)-339.07M
Diluted EPS (ttm)-5.15
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)436.58M
Total cash per share (mrq)5.9
Total debt (mrq)6.56M
Total debt/equity (mrq)1.16%
Current ratio (mrq)6.85
Book value per share (mrq)7.67

Cash flow statement

Operating cash flow (ttm)-239.91M
Levered free cash flow (ttm)-120.9M